Welcome David Enloe as new CEO of Oregon Freeze Dry! #PortfolioCompanyNews #Leadership
Oregon Freeze Dry Brings in New Leadership Life Sciences CDMO Veteran David Enloe Appointed CEO Oregon Freeze Dry, one of North America’s largest and most technologically advanced freeze-dryer of foods, probiotics, enzymes, proteins, and other lyophilized pharmaceutical inputs, has named J. David Enloe Jr. as Chief Executive Officer. Enloe brings nearly three decades of executive leadership experience in biopharmaceutical innovation, therapeutic drug and vaccine development, and cGMP manufacturing. OFD is owned by Arbor Investments, a specialized private equity firm that focuses principally on acquiring premier companies in food, beverage, and related industries.? “David is a dynamic leader who knows how to keep organizations focused and motivated to ultimately deliver outstanding results,” said John Jordan, Chief Operating Officer at Arbor.?“In addition to his broad skillset, his deep understanding of the biopharma and the life sciences sector will undoubtedly play a pivotal role in driving growth at OFD.” “I’m very excited to have the opportunity to lead OFD into the next chapter of its impressive legacy as a leading provider of lyophilized product solutions. By leveraging the Company’s technical and innovation-focused expertise in the food and related markets, OFD is now poised to deploy that manufacturing and quality expertise to additional markets, including the animal health and biopharmaceutical sectors,” said Enloe. Before joining OFD, Enloe served as President and CEO of Societal CDMO, Inc. (formerly Recro Pharma), a publicly traded contract development and manufacturing organization (CDMO) for which Enloe engineered a take-private transaction to a leading life sciences private equity firm. ?Prior to Societal CDMO, Enloe was President and Chief Executive Officer of Ajinomoto Bio-Pharma Services, a global, fully integrated CDMO which was the result of merging four distinct CDMOs under Enloe’s vision and leadership. In 2009 Enloe founded one of the first gene therapy CDMOs, Vivante GMP Solutions, which he sold to Switzerland-based Lonza and which was the basis for establishing Lonza’s Viral Therapeutics Business Unit, which Enloe led for three years after its sale.?His entry into the life sciences space was as the first employee, Senior Vice President of Operations, and ultimately CEO of Introgen Therapeutics, Inc., one of the first gene therapy development companies in the world, where he oversaw the creation of the first commercial scale viral vector facility in the United States. Enloe received a Bachelor of Business Administration, Accounting from the University of Texas at Austin. He is a Certified Public Accountant and started his career in public accounting with Arthur Andersen & Co.